Gene therapy injection aims to ease diabetic eye swelling
NCT ID NCT07362927
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a gene therapy called LX111 for diabetic macular edema (DME), a condition that causes vision loss due to swelling in the retina. About 32 adults with DME will receive a single injection into the eye. The main goals are to check safety and see if it helps improve vision and reduce swelling.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA (DME) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai General Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Zhongshan Hospital
NOT_YET_RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact